REUN Stock Performance, Insider Transaction and News

REUN - Reunion Neuroscience Inc.

Market Cap	13.01M	P/E	-	EPS this Y	-90.70%	Ern Qtrly Grth	-
Income	-38.1M	Forward P/E	-1.61	EPS next Y	-	50D Avg Chg	7.00%
Sales	-	PEG	-	EPS past 5Y	-	200D Avg Chg	-
Dividend	N/A	Price/Book	0.61	EPS next 5Y	-	52W High Chg	-95.00%
Recommedations	3.00	Quick Ratio	3.29	Shares Outstanding	11.72M	52W Low Chg	76.00%
Insider Own	34.39%	ROA	-26.51%	Shares Float	2.83M	Beta	4.20
Inst Own	50.66%	ROE	-86.35%	Shares Shorted/Prior	114.90K/179.32K	Price	1.11
Gross Margin	-	Profit Margin	-	Avg. Volume	436,454	Target Price	1.00
Oper. Margin	-	Earnings Date	Jun 29	Volume	19,005	Change	0.00%

Healthcare | Biotechnology | Canada

About Reunion Neuroscience Inc.

Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company, develops therapeutic solutions for mental health conditions in North America. The company's lead asset includes RE104, a clinical-stage serotonergic psychedelic therapeutic product for antidepressant applications. It is also developing the RE200 series, which comprises molecules that are structurally designed to be similar to classical psychedelics with selective potency at the target serotonin 2A receptor (5HT2A) for potential chronic treatment in various patient populations and indications. The company was formerly known as Field Trip Health Ltd. Reunion Neuroscience Inc. was founded in 2008 and is headquartered in Toronto, Canada.

REUN Chatroom

DonCorleone77 Posted - 05/20/24

$REUN Reunion Neuroscience announces publication of results from RE104 studies Reunion Neuroscience announced the publication of the results of preclinical studies in ACS Chemical Neuroscience that validate the decisions to pursue RE104, a proprietary, patented prodrug of 4-OH-DiPT as a potential therapeutic in depressive disorders. The paper, titled "RE104: Synthesis and Activity of a Novel Serotonergic Psychedelic Prodrug of 4-Hydroxy-N,N-diisopropyltryptamine," was co-authored by Robert Alexander, Ph.D., Reunion's Chief Medical Officer, and Michael D. Ehlers, M.D., Ph.D., Chief Scientific Officer and Venture Partner at Apple Tree Partners, with Nathan Bryson, Ph.D., Reunion's Chief Scientific Officer, as senior author. "Serotonergic psychedelic compounds have demonstrated significant potential to treat a variety of mental health disorders," said Nathan Bryson, Ph.D., Chief Scientific Officer of Reunion. "The preclinical data published in ACS Chemical Neuroscience was the impetus for selecting 4-OH-DiPT as the psychedelic substrate at the core of our development program, as well as the choice of the RE104 prodrug strategy for its delivery. The findings present evidence supporting our target profile of an antidepressant drug product with reproducible pharmacokinetics, a short duration of psychoactivity, as well as fast-onset and durable action in depression." RE104 is a 4-OH-DiPT prodrug comprising a glutarate pro-moiety that cleaves rapidly in situ, providing excellent bioavailability of the active drug shortly after administration. The newly published study describes the synthesis, as well as the chemical, preclinical, and translational characterization of RE104, including conversion to 4-OH-DiPT and subsequent metabolism in vivo. In a forced swim model of behavior to assess antidepressive activity, RE104 demonstrated efficacy similar to a psilocybin analog at Day 7, 14 and 28. This study used RE109, a psilocin prodrug of similar structure to RE104, which is also described in the paper.

Stock_Titan Posted - 7 months ago

$REUN Reunion Neuroscience Inc. Announces Upcoming Presentations at the Anxiety and Depression Association of America (ADAA) 2024 Conference https://www.stocktitan.net/news/REUN/reunion-neuroscience-inc-announces-upcoming-presentations-at-the-45eu50t3mn55.html

TrendyChart Posted - 10/30/23

Upcoming Earnings Report: $REUN Reunion Neuroscience will be reporting on 11/10/2023 at 4:00PM | What's your outlook on this stock's earnings?

Stock_Titan Posted - 1 year ago

$REUN Reunion Neuroscience Inc. to Participate in October Investor Conferences https://www.stocktitan.net/news/REUN/reunion-neuroscience-inc-to-participate-in-october-investor-o0m4iefk7mfa.html

TrendyChart Posted - 1 year ago

Upcoming Earnings Report: $REUN Reunion Neuroscience will be reporting on 10/13/2023 at 4:00PM | Do you believe in the potential for strong or weak earnings performance?

DonCorleone77 Posted - 09/18/23

$REUN Reunion Neuroscience receives FDA clearance of IND application for RE104 study Reunion Neuroscience announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application to initiate a Phase 2 study of RE104, a novel serotonergic psychedelic compound, for the treatment of postpartum depression. The Phase 2 study, the RECONNECT Trial, is a multicenter, randomized, double-blind, parallel-group, active-dose placebo-controlled study, which will evaluate the safety and efficacy of a single subcutaneous dose of RE104 in adult female patients with PPD. The study is expected to begin in Q4 2023 with a targeted data readout in late 2024.

Stock_Titan Posted - 09/18/23

$REUN Reunion Neuroscience Inc. Announces FDA Clearance of IND Application to Initiate a Phase 2 Study of RE104 for the Treatment of Postpartum Depression https://www.stocktitan.net/news/REUN/reunion-neuroscience-inc-announces-fda-clearance-of-ind-application-wvecs3rebfw5.html

stockilluminati Posted - 08/18/23

$REUN https://www.stockilluminati.com/reun/filings.php - Reunion Neuroscience Inc. - Common Shares files form 15-12G today, check out the details.

Quantisnow Posted - 08/18/23

$REUN 📜 SEC Form 15-12G filed by Reunion Neuroscience Inc. https://quantisnow.com/i/4916662?utm_source=stocktwits 45 seconds delayed.

risenhoover Posted - 08/18/23

$REUN / Reunion Neuroscience files form 15-12G https://fintel.io/sf/us/reun?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=filing

ChartMill Posted - 1 year ago

$REUN: The long and short term trends are both positive. This is looking good! https://www.chartmill.com/stock/quote/REUN/technical-analysis?key=7cfce831-ddfa-4048-a11c-07ea15c06305&utm_source=TA&utm_medium=stocktwits&utm_campaign=TA&utm_content=REUN

tickeron Posted - 1 year ago

Reunion Neuroscience to report earnings on August 15, 2023. Earnings per share (EPS) estimate: $-0.29 $REUN https://srnk.us/go/4830935

tickeron Posted - 1 year ago

A fresh look at the market situation, isn't it? $REUN in Downtrend: RSI indicator exits overbought zone. View odds for this and other indicators: https://srnk.us/go/4821230

SlickB Posted - 1 year ago

$REUN scumbag company

swingingtech Posted - 1 year ago

$REUN https://wallstreetwaves.com/reunion-neuroscience-completes-take-private-setup-delisting-consideration-details/